share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  07/16 17:33
Moomoo AI 已提取核心信息
On July 16, 2024, 60 Degrees Pharmaceuticals, Inc. conducted its 2024 Annual Stockholders Meeting virtually. During the meeting, a quorum was established with approximately 51.86% of the outstanding voting shares represented. Five director nominees were elected to serve until the 2025 annual meeting. Additionally, stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for issuance by 5 million. A reverse stock split of the common stock was also approved, with a ratio range from 1:5 to 1:12, to be determined by the Board of Directors. Modifications to the strike price of options for the CEO and CFO, as well as the issuance of options to a consultant, were approved to comply with Nasdaq Listing Rule 5635(c). Furthermore, RBSM LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024. The meeting concluded with all proposals receiving the required majority approval from the shares represented.
On July 16, 2024, 60 Degrees Pharmaceuticals, Inc. conducted its 2024 Annual Stockholders Meeting virtually. During the meeting, a quorum was established with approximately 51.86% of the outstanding voting shares represented. Five director nominees were elected to serve until the 2025 annual meeting. Additionally, stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for issuance by 5 million. A reverse stock split of the common stock was also approved, with a ratio range from 1:5 to 1:12, to be determined by the Board of Directors. Modifications to the strike price of options for the CEO and CFO, as well as the issuance of options to a consultant, were approved to comply with Nasdaq Listing Rule 5635(c). Furthermore, RBSM LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024. The meeting concluded with all proposals receiving the required majority approval from the shares represented.
2024年7月16日，60度药业股份有限公司在虚拟方式下进行了2024年股东大会。会议期间，以约51.86%的表决权代表未行使表决权的股份数为基数，建立了法定人数。五名董事候选人当选，任期至2025年股东大会。此外，股东批准了2022年股权激励计划的修正案，将可发行股票数增加了500万。对于普通股的反向股票分割，比率在1：5至1：12的区间范围内，由董事会决定。批准首席执行官和首席财务官期权行权价的修改，以及向顾问发放期权，以符合纳斯达克上市规则5635(c)。此外，RBSm LLP被批准为截至2024年12月31日的财年的独立审计师。会议以所有提议均获得代表股份所需的多数批准结束。
2024年7月16日，60度药业股份有限公司在虚拟方式下进行了2024年股东大会。会议期间，以约51.86%的表决权代表未行使表决权的股份数为基数，建立了法定人数。五名董事候选人当选，任期至2025年股东大会。此外，股东批准了2022年股权激励计划的修正案，将可发行股票数增加了500万。对于普通股的反向股票分割，比率在1：5至1：12的区间范围内，由董事会决定。批准首席执行官和首席财务官期权行权价的修改，以及向顾问发放期权，以符合纳斯达克上市规则5635(c)。此外，RBSm LLP被批准为截至2024年12月31日的财年的独立审计师。会议以所有提议均获得代表股份所需的多数批准结束。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息